Premium
Expressions of p53 and PUMA in fibroblasts of systemic sclerosis patients are normal at transcription level
Author(s) -
Mahmoudi Mohammad Bagher,
Abed Khojasteh Majid,
Alsahebfosoul Fereshteh,
Gharibdoost Farhad,
Mostafaei Shayan,
Ganjalikhanihakemi Mazdak,
Mahmoudi Mahdi
Publication year - 2018
Publication title -
journal of cosmetic dermatology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.626
H-Index - 44
eISSN - 1473-2165
pISSN - 1473-2130
DOI - 10.1111/jocd.12420
Subject(s) - puma , apoptosis , fibroblast , fibrosis , messenger rna , sybr green i , downregulation and upregulation , biology , real time polymerase chain reaction , microbiology and biotechnology , cancer research , medicine , gene , pathology , cell culture , genetics
Summary Background Systemic sclerosis ( SS c) fibroblasts show resistance apoptosis mechanisms, which enhances the fibrosis stage of the disease. Impaired function of p53 upregulated modulator of apoptosis ( PUMA ) has been related to deficits in p53‐dependant apoptosis pathway. This study aimed to evaluate the transcriptional levels of p53 and PUMA mRNA s in fibroblasts from SS c patients and compare it with healthy individuals. Methods In this case‐control study, skin biopsy samples were obtained from 19 patients with diffuse cutaneous SS c (Dc SS c) and 16 healthy controls. Afterward, dermal fibroblasts were isolated and cultured. After extraction of total RNA from cultured fibroblasts, complementary DNA ( cDNA ) was synthesized. mRNA quantification was carried out using real‐time PCR , SYBR Green PCR master mix, and specific primers for p53 and PUMA. Results No significant alteration was observed in mRNA expression levels of p53 and PUMA ( P = .99 and .23, respectively) in fibroblasts from SS c patients compared with controls. Conclusions Apoptosis pathways are impaired in fibroblasts from patients with SS c, leading to chronic fibrosis. Nonetheless, PUMA /p53 pathway may not be involved in dysfunction of apoptosis mechanisms in fibroblasts of patients with SS c.